Rande Is . . . HOME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: OpusX who wrote (13399)	10/13/1999 10:25:00 AM
From: John Miz	Read Replies (1) of 57584

ALLP NEWS. Submits NDA to FDA. marketwatch.newsalert.com. SAN DIEGO, Oct. 13 /PRNewswire/ -- Alliance Pharmaceutical Corp. (Nasdaq: ALLP) announced today that a New Drug Application (NDA) has been submitted to the Food and Drug Administration (FDA) for approval of Imagent(R) (AF0150), an ultrasound contrast agent. The NDA includes clinical data from two Phase 3 studies with Imagent that successfully demonstrated a clinically and highly statistically significant improvement in visualization of the walls of the heart (endocardial border delineation) compared to standard (non-contrasted) ultrasound imaging. Enhanced visualization of the heart may allow better detection of cardiac abnormalities such as structural and functional defects. Imagent is being developed jointly by Alliance and Schering AG, Germany, and will be marketed worldwide exclusively by Schering AG. ------

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next